Compare IDT & AMPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IDT | AMPH |
|---|---|---|
| Founded | 1990 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.2B |
| IPO Year | 1996 | 2014 |
| Metric | IDT | AMPH |
|---|---|---|
| Price | $48.26 | $29.26 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $31.00 |
| AVG Volume (30 Days) | 139.9K | ★ 330.6K |
| Earning Date | 03-05-2026 | 02-26-2026 |
| Dividend Yield | ★ 0.49% | N/A |
| EPS Growth | ★ 10.35 | N/A |
| EPS | ★ 3.22 | 2.27 |
| Revenue | ★ $1,244,681,000.00 | $723,305,000.00 |
| Revenue This Year | $1.99 | $1.37 |
| Revenue Next Year | N/A | $4.84 |
| P/E Ratio | $15.06 | ★ $12.62 |
| Revenue Growth | ★ 2.52 | N/A |
| 52 Week Low | $45.07 | $20.39 |
| 52 Week High | $71.12 | $33.42 |
| Indicator | IDT | AMPH |
|---|---|---|
| Relative Strength Index (RSI) | 46.63 | 66.12 |
| Support Level | $46.63 | $28.45 |
| Resistance Level | $49.75 | $29.37 |
| Average True Range (ATR) | 1.22 | 0.86 |
| MACD | 0.01 | 0.28 |
| Stochastic Oscillator | 61.85 | 93.33 |
IDT Corp is a multinational holding company. It operates in the telecommunications and payment industries. It has four reportable business segments, Fintech, National Retail Solutions; net2phone and Traditional Communications, The Fintech segment is comprised of National Retail Solutions (NRS), an operator of a nationwide point of sale (POS) network providing payment processing, digital advertising, transaction data, and ancillary services, and BOSS Money, a provider of international money remittance and related value/payment transfer services. The net2phone segment provides unified cloud communications and telephony services to business customers.
Amphastar Pharmaceuticals Inc is a bio-pharmaceutical company focusing on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products, as well as insulin active pharmaceutical ingredient, or insulin API products. The company's finished products are used in hospital or urgent care clinical settings and are contracted and distributed through group purchasing organizations and drug wholesalers. The company has one reportable segment pharmaceutical products. Geographically the business presence of the firm is seen in the United States, China and France of which the U.S. accounts for the majority of the revenue.